TFRC and sarcoma: This study aimed to evaluate the possibility to utilize type 1 RIP-containing conjugates, hereafter referred to as ITs, to selectively target TfR1-, EGFR1- and Her2-expressing sarcoma cells in bidimensional and tridimensional models.